Rapamycin
Hepatoblastoma
Emory UniversityPhase 1Dormant
CC
46/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 89/ 100
Competitive context
44 Active assets in the Hepatoblastoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cyclophosphamide St. Jude Children's Research Hospital | Phase 2 | BB |
(+)-VINCRISTINE University of Birmingham | Phase 3 | BB |
ETOPOSIDE Children's Oncology Group | Phase 3 | BB |
Eloxatin Children's Oncology Group | Phase 3 | BB |
Carboplatin Children's Oncology Group | Phase 3 | BB |
View all 50 →
Same molecule, other indications
Rapamycin is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →